Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

(2009) A. M. Jankowska et al.   BLOOD

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

(2009) Philip A. Beer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

(2009) M W Drummond et al.   LEUKEMIA

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

(2009) Chen Zhao et al.   NATURE

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Glycogen synthase kinase 3  missplicing contributes to leukemia stem cell generation

(2009) A. E. Abrahamsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

The yin and yang of lenalidomide

(2008) N. E. Kay   BLOOD

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

(2008) S. Li et al.   BLOOD

Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells

(2008) A. Zeuner et al.   BLOOD

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F

(2008) F. X. Schaub et al.   BLOOD

Nuclear translocation of urokinase-type plasminogen activator

(2008) V. Stepanova et al.   BLOOD

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

(2008) C. G. Mullighan et al.   BLOOD

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

(2008) S. Xing et al.   BLOOD

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A

(2008) X. Zhang et al.   BLOOD

RGT, a synthetic peptide corresponding to the integrin  3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin  IIb 3 with Src kinase

(2008) X. Su et al.   BLOOD

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

(2008) Daniela Capello et al.   BRITISH JOURNAL OF HAEMATOLOGY

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

(2008) Danilo Perrotti et al.   CANCER AND METASTASIS REVIEWS

Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation

(2008) Christine Dierks et al.   CANCER CELL

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders

(2008) Ruben A Mesa   CURRENT OPINION IN HEMATOLOGY

Aberrant expression of microRNA in polycythemia vera

(2008) H. Bruchova et al.   HAEMATOLOGICA

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

(2008) N. Fourouclas et al.   HAEMATOLOGICA

5-Azacitidine has limited therapeutic activity in myelofibrosis

(2008) R A Mesa et al.   LEUKEMIA

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

(2008) A Quintás-Cardama et al.   LEUKEMIA

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE

Inhibition of the Bcl-xLDeamidation Pathway in Myeloproliferative Disorders

(2008) Rui Zhao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

BCR-ABL-transformed GMP as myeloid leukemic stem cells

(2008) Y. Minami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia

(2008) Francis J. Giles et al.   SEMINARS IN ONCOLOGY

Hypermethylation ofCXCR4Promoter in CD34+Cells from Patients with Primary Myelofibrosis

(2008) Costanza Bogani et al.   STEM CELLS

The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?

(2008) C. James   Hematology-American Society of Hematology Education Program

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD